

FOI Request: RNIB

Our Reference Number: 1314394

*We would like to request the following information on the four treatments listed below:*

- Are the four treatments listed below routinely available to patients under the indications specified by the below NICE TAGs in your CCG area?*
- Details of any additional criteria to the TAG criteria / interpretation of the TAG criteria which is placed on the availability of these four treatments*
- The number of patients treated with each treatment in line with the indication specified in the TAG since the time when each treatment should have been available to patients (which is listed below alongside each treatment name)*
- The number of Individual Funding Requests made for each treatment since the date when the treatment should have been made available to patients (which is listed below alongside each treatment name).*

*If the any of the treatments are not routinely available to patients under the specified indications (below) or require an Individual Funding Request in order to access the treatment then please also provide:*

- Meeting minutes of meetings since November 2012 in which the approval of use of that treatment has been discussed.*

- 1. Ocriplasmin**
- 2. Aflibercept**
- 3. Ranibizumab (TA283)**
- 4. Ranibizumab (TA274)**

Answers are the same for all 4 treatments:

- Yes these treatments are routinely available as per the NICE TAGs
- There are no additional criteria
- We don't hold information on the numbers of patients treated
- We have had no IFRs for these treatments